Fluoroquinolone drugs such as Levaquin, Avelox and Cipro have been linked to a higher risk of nerve damage in patients, whether through injections or oral medications. As a result, the FDA issued new s in all Fluoroquinolone labels and guides. The decision was reached after the FDA reviewed dozens of adverse event reports and found that these antibiotics may be linked to the development of peripheral neuropathy. These new FDA guidelines stipulated that this specific side effect could no longer be described on the label as “rare,” citing the “potential rapid onset and permanence” of the neuropathy. Recently Fluroquinolones have been linked to aortic aneurysms and aortic dissections, both potentially deadly conditions. An aortic aneurysm is a bulge in part of the aorta, the body’s main artery. This bulge can cause the aorta to burst, causing severe blood loss and in some cases death. An aortic dissection occurs when the inner layer of the aorta tears, and may cause blood to rush into the space between the inner aortic wall and the outer aortic wall many times resulting in death. The current FDA labeling doesn’t include the risk of aortic aneurysm.